邵氏“五针法”治疗活动期溃疡性结肠炎临床观察

Clinical Observation of SHAO's Five-needle Therapy for Active Ulcerative Colitis

目的观察邵氏"五针法"治疗活动期溃疡性结肠炎的临床疗效。方法采用随机对照法将57例活动期溃疡性结肠炎患者分为肺肠同治组28例、治肠组29例。肺肠同治组采用邵氏"五针法"加药物治疗,包括口服美沙拉嗪、柳氮磺吡啶栓纳肛、葛根芩连汤灌肠;治肠组采用药物治疗。两组均连续治疗4周,观察两组治疗前后Sutherland疾病活动指数(Sutherland DAI);记录两组治疗前后主要临床症状、体征评分。结果两组治疗后Sutherland DAI评分均较治疗前下降(P<0.05),组间比较差异有统计学意义(P<0.05);两组治疗后腹痛、腹泻、脓血便均较治疗前下降(P<0.05),组间比较差异有统计学意义(P<0.05);两组临床疗效比较,肺肠同治组优于治肠组(P<0.05)。结论邵氏"五针法"联合药物治疗能够快速缓解患者的临床症状、体征,减少Sutherland DAI,提高临床疗效。

Objective To observe the clinical efficacy of SHAO’s five-needle therapy in treating active ulcerative colitis.Method By following a randomized controlled design,57 patients with active ulcerative colitis were divided into a lung-intestine simultaneous treatment group of 28 cases and an intestine treatment group of 29 cases.The lung-intestine simultaneous treatment group was intervened by SHAO’s five-needle therapy plus medications including oral administration of mesalazine,sulfasalazine suppositories via rectal insertion and Ge Gen Qin Lian decoction via enema;the intestine treatment group was intervened by medications.The two groups were both treated successively for 4 weeks.The Sutherland Disease Activity Index(Sutherland DAI)was observed in the two groups and the release rate was also assessed;the main clinical symptom and sign scores of the two groups were recorded before and after treatment.Result The Sutherland DAI score dropped after treatment in both groups(P<0.05),and the between-group difference was statistically significant(P<0.05);the scores of abdominal pain,diarrhea and stool mixed with pus and blood declined after treatment in both groups(P<0.05),and the between-group differences were statistically significant(P<0.05);the lung-intestine simultaneous treatment group was superior to the intestine treatment group comparing plus medications the therapeutic efficacy regarding the symptoms and signs(P<0.05).Conclusion SHAO’s five-needle therapy can rapidly release the clinical symptoms and body signs of active ulcerative colitis and enhance the clinical efficacy.